Mark Levine

Image006 3e

Dr. Levine is the founding Scientific Director of the Escarpment Cancer Research Institute.

Mark Levine is Chair and Professor in the Department of Oncology at McMaster University, Hamilton, Ontario.  He holds the Buffett Taylor Chair in Breast Cancer Research at McMaster.  He is a past recipient of the O. Harold Warwick Prize (1999) from the National Cancer Institute of Canada.  In 2012 he became a Fellow of the American Society of Clinical Oncology.

Dr. Levine received his medical degree from McGill University, Montreal, Quebec and completed his residency in internal medicine at McMaster University.  He completed his training in hematology and oncology at Duke University Medical Centre, Durham, North Carolina, USA.  In addition, Dr. Levine received a master’s degree in clinical epidemiology and biostatistics from McMaster.

In 1982, Dr. Levine became a member of both the Faculty of Health Sciences at McMaster University, and a medical oncologist at the Hamilton Regional Cancer Centre (now known as the Juravinski Cancer Centre - Hamilton Health Sciences).  He was CEO of the Cancer Centre between 1992 and 1999.  Over the past 32 years he has been an active researcher in clinical trials and health services research and has achieved distinction as a leader in oncology and hematology research.  His research on adjuvant chemotherapy for early breast cancer has influenced the treatment of breast cancer nationally and internationally.  He led trials that have changed clinical practice worldwide, e.g. treating patients with acute venous thromboembolism (VTE) at home with low molecular weight heparin (LMWH) rather than in hospital with IV heparin, and treating cancer patients with acute VTE with six months of LMWH instead of warfarin.  He helped establish the Ontario Clinical Oncology Group (OCOG) in 1982 and now is the Director.  OCOG is an academic group that designs, coordinates and analyses multicentre trials in cancer and thrombosis.

Some of Dr. Levine’s most impactful contributions have arisen through research conducted by OCOG, e.g. a program of trials evaluating PET imaging in oncology that have influenced policy in Ontario.  In 2011, he realised a dream by establishing the Escarpment Cancer Research Institute, a joint research institute of McMaster University and Hamilton Health Sciences.

He has over 280 publications in peer-reviewed journals and has brought much research funding to McMaster.  He has mentored many young researchers.  He was Chairman of Health Canada’s Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.  Dr. Levine was an Associate Editor of the Journal of Clinical Oncology for seven years and now is a Consultant Editor.

Key Publications:

Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu‑Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D for the National Cancer Institute of Canada Clinical Trials Group.  Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer.  Journal of Clinical Oncology 16:2651-2658, 1998.

Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S and Willan A. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine 334:677-681, 1996.

Moulton CA, Gu CS, Law CH, Tandan VR, Hart R, Quan D, Fairfull Smith RJ, Jalink DW, Husien M, Serrano PE, Hendler AL, Haider MA, Ruo L, Gulenchyn KY, Finch T, Julian JA, Levine MN, Gallinger S. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial.  [Epub: JAMA doi: 10.1001/jama.2014.3740]  JAMA 311(18):1863-9, 2014.


News for prostate cancer treatment


ECRI Scientists have been busy.